FRANKFURT (dpa-AFX) - Bayer shares are the weakest DAX stock this week with a slump of around 21 percent. The day before, at the low since 2006 of 32.24 euros, it was still a good one percent higher. The week began with some very bad news. A multi-billion euro glyphosate court defeat in the USA and the end of a clinical trial for the pharmaceutical hopeful Asundexian.

Some analysts have since downgraded Bayer shares. Kepler Cheuvreux also followed suit on Friday. The news situation is likely to continue to weigh on the company, even after the previous price slide, they said. With the discontinuation of the anticoagulant Asundexian, "a decisive piece of the puzzle is now missing from the pipeline". In addition, high inventories in the agrochemical sector threatened to spoil the start of 2024. The Kepler experts cut the price target to around the current Xetra level at 33 euros./ag/jha/